Cambridge, UK, October 22 2019: o2h discovery is pleased to announce a significant expansion in its existing Synthetic Chemistry collaboration with Sosei Heptares, an international biopharmaceutical group focused on the design and development of new medicines originating from its proprietary GPCR-targeted StaR® technology and Structure-Based Drug Design platform capabilities.
o2h discovery supports biotechnology and pharmaceutical companies with drug discovery support from its research facility in Ahmedabad, India and is developing additional discovery biology capabilities from The Mill SciTech Park in Cambridge, UK which the o2h group recently acquired.
John Christopher, Director of Medicinal Chemistry at Sosei Heptares noted that: “Sosei Heptares has a long-standing collaboration with o2h discovery that has consistently delivered good value synthetic chemistry support across a number of our projects with flexible, fast delivery and excellent communication. We are delighted to be extending our interactions further though a significant expansion to the current team.”
Sunil Shah, CEO, o2h discovery, said “o2h discovery is delighted to deepen its collaboration with Sosei Heptares; a relationship that has spanned over a decade. We appreciate the confidence that the Sosei Heptares team place in o2h discovery and it is a privilege to provide to support the team with their discovery efforts”.
About o2h discovery:
o2h discovery has an integrated drug discovery platform operating from our state-of-the-art research center in Ahmedabad, India and The Mill SciTech Park, Cambridge, UK. We have the in-house capability to execute hit-lead-optimization programs leading into patent and IND filing from with expertise in discovery chemistry, biology, pharmacology and the on-going project management of pre-clinical development.
o2h discovery has developed and launched its proprietary application AI Chemistry in the CloudTM (AI-CITC) which is the world’s first app to revolutionize the project management of external drug discovery programs. The app enables communication between various scientific stakeholders essential to successful project advancement – leading to faster decision making.
The DNA of the o2h group is centered around the nurturing of its people, values and culture, it reflects in the way we work with each other, as well as our collaborators and partners. The vision of the o2h group is to seed new ideas in life-science, technology and social enterprise.
For more information, please visit www.o2h.com
PR and Communications, o2h discovery
About Sosei Heptares:
Sosei Heptares is an international biopharmaceutical group focused on the design and development of new medicines originating from its proprietary GPCR-targeted StaR® technology and structure-based drug design platform capabilities. It is advancing a broad and deep pipeline of novel medicines across multiple therapeutic areas, including CNS, immuno-oncology, gastroenterology, inflammation and other rare/specialty indications. Its leading clinical programs include partnered candidates aimed at the symptomatic treatment of Alzheimer’s disease (with Allergan) and next-generation immuno-oncology approaches to treat cancer (with AstraZeneca).
Additional partners and collaborators include Takeda, Genentech, Novartis, Pfizer, Daiichi-Sankyo, PeptiDream, Kymab, MorphoSys. Sosei Heptares is headquartered in Tokyo, Japan with R&D facilities in Cambridge, UK.
“Sosei Heptares” is the corporate brand of Sosei Group Corporation, which is listed on the Tokyo Stock Exchange (ticker: 4565).
For more information, please visit https://www.soseiheptares.com/ or follow Sosei Heptares on LinkedIn: @soseiheptaresco | Twitter: @soseiheptaresco | YouTube: @soseiheptaresco
Media Contact for Sosei Heptares:
Mark Swallow/David Dible, Citigate Dewe Rogerson
+44 (0)20 7638 9571